Company profile
PRECIGEN, INC.
NASDAQ:PGENBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Zopapogene Imadenovec | approved | — | 1 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (6)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03751007 | phase1_2 | completed | 2018-10-24 | 2021-10-13 | Precigen Actobio T1D, LLC | A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D) |
| NCT04724980 | phase1_2 | active_not_recruiting | 2021-03-16 | 2024-06-05 | Precigen, Inc | Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis |
| NCT03907527 | phase1 | active_not_recruiting | 2019-04-30 | 2024-12-15 | Precigen, Inc | Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer |
| NCT06157151 | phase2 | recruiting | 2025-11-11 | 2026-11-11 | Precigen, Inc | PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer |
| NCT03927261 | phase1 | active_not_recruiting | 2019-05-20 | 2024-08-01 | Precigen, Inc | PRGN-3006 Adoptive Cellular Therapy for CD33-Positive Relapsed or Refractory AML, MRD Positive AML or Higher Risk MDS |
FDA applications (1)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 125832 | BLA | Precigen, Inc. | ||||
Loading… | ||||||